IBA Announces Expansion of Collaboration with MorphoSys AbD Serotec
News Nov 13, 2006
IBA GmbH (Goettingen) has announced the signing of a second license agreement with MorphoSys AG regarding recombinant antibody purification using IBA’s proprietary Strep-tag® technology.
The original research license agreement dating back to the year 2000 has now been complemented with a second license agreement rendering the commercial use of IBA’s Strep-tag patent rights for custom service purification of antibodies by AbD Serotec, a business unit of MorphoSys AG.
The license granted by IBA is worldwide and non-exclusive. Recent IBA developments in the Strep-tag field had proven to be advantageous compared to other tag-systems for automated batch purification of recombinant antibodies.
"We are very pleased to announce an expansion of one of our earliest and most productive Strep-tag out-licensing opportunities to date," commented Alois Schneiderbauer, Chief Business Officer of IBA.
"Expanding our existing collaborations is a cornerstone of our strategy and we have been very successful in this regard."
"The extended agreement provides a higher number of antibodies carrying a Strep-tag to the market, allowing e.g. for their convenient detection and immobilisation."